Precision BioSciences Inc (DTIL) - Total Liabilities
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has total liabilities worth $67.79 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Precision BioSciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
Precision BioSciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. See DTIL free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Precision BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Precision BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Helloworld Travel Ltd
AU:HLO
|
Australia | AU$231.83 Million |
|
Niko Semiconductor Co Ltd
TWO:3317
|
Taiwan | NT$638.21 Million |
|
Niu Technologies
NASDAQ:NIU
|
USA | $2.41 Billion |
|
Verb Technology Company Inc
NASDAQ:VERB
|
USA | $22.42 Million |
|
Soechi Lines Tbk
JK:SOCI
|
Indonesia | Rp203.62 Million |
|
Les Hotels Bav
PA:ALLHB
|
France | €27.80 Million |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
Taiwan | NT$3.53 Billion |
|
Li Peng Enterprise Co Ltd
TW:1447
|
Taiwan | NT$7.65 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Precision BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Precision BioSciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precision BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precision BioSciences Inc (2016–2025)
The table below shows the annual total liabilities of Precision BioSciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.17 Million | -22.29% |
| 2024-12-31 | $80.00 Million | -43.23% |
| 2023-12-31 | $140.92 Million | -20.71% |
| 2022-12-31 | $177.74 Million | +47.71% |
| 2021-12-31 | $120.33 Million | +13.81% |
| 2020-12-31 | $105.73 Million | +9.09% |
| 2019-12-31 | $96.92 Million | -1.74% |
| 2018-12-31 | $98.64 Million | -0.41% |
| 2017-12-31 | $99.05 Million | -3.99% |
| 2016-12-31 | $103.16 Million | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more